Abstract
A large number of herbal remedies (e.g. garlic, mistletoe, Essiac, Lingzhi, and astragalus) are used by cancer patients for treating the cancer and/or reducing the toxicities of chemotherapeutic drugs. Some herbal medicines have shown potentially beneficial effects on cancer progression and may ameliorate chemotherapy-induced toxicities. However, there is no or weak scientific basis for the clinical use of these herbal medicines in cancer management and almost none of these plant medicines have been tested in rigorous clinical trials. There are increased reports on the interaction of herbal medicines and anticancer drugs that is becoming a safety concern. For example, a clinical study in cancer patients reported that treatment of St Johns wort at 900 mg/day orally for 18 days decreased the plasma levels of the active metabolite of irinotecan, SN-38, by 42%. In healthy subjects, 2 weeks of treatment with St Johns wort at 900 mg/day significantly decreased the systemic exposure of imatinib by 32%. In women with advanced breast cancer, coadministration of garlic supplement reduced the clearance of docetaxol by 23.1-35.1%, although the difference did not achieve statistical significance. Most anticancer drugs undergo Phase I and/or II metabolism and are substrates of P-glycoprotein, breast cancer resistance protein, multidrug resistance associated proteins, and/or other transporters. Induction and inhibition of these enzymes and transporters are considered as important mechanisms for herb-anticancer drug interactions. Further studies are warranted to investigate potentially harmful herbal interactions with anticancer drugs in patients.
Keywords: Anticancer drug, herbal medicine, herb-drug interaction, toxicity, pharmacokinetics, cytochrome P450, P-glycoprotein, St John's wort, drug resistance
Current Medicinal Chemistry
Title: Herbal Interactions with Anticancer Drugs: Mechanistic and Clinical Considerations
Volume: 17 Issue: 16
Author(s): An-Kui Yang, Shu-Ming He, Liang Liu, Jun-Ping Liu, Ming Qian Wei and Shu-Feng Zhou
Affiliation:
Keywords: Anticancer drug, herbal medicine, herb-drug interaction, toxicity, pharmacokinetics, cytochrome P450, P-glycoprotein, St John's wort, drug resistance
Abstract: A large number of herbal remedies (e.g. garlic, mistletoe, Essiac, Lingzhi, and astragalus) are used by cancer patients for treating the cancer and/or reducing the toxicities of chemotherapeutic drugs. Some herbal medicines have shown potentially beneficial effects on cancer progression and may ameliorate chemotherapy-induced toxicities. However, there is no or weak scientific basis for the clinical use of these herbal medicines in cancer management and almost none of these plant medicines have been tested in rigorous clinical trials. There are increased reports on the interaction of herbal medicines and anticancer drugs that is becoming a safety concern. For example, a clinical study in cancer patients reported that treatment of St Johns wort at 900 mg/day orally for 18 days decreased the plasma levels of the active metabolite of irinotecan, SN-38, by 42%. In healthy subjects, 2 weeks of treatment with St Johns wort at 900 mg/day significantly decreased the systemic exposure of imatinib by 32%. In women with advanced breast cancer, coadministration of garlic supplement reduced the clearance of docetaxol by 23.1-35.1%, although the difference did not achieve statistical significance. Most anticancer drugs undergo Phase I and/or II metabolism and are substrates of P-glycoprotein, breast cancer resistance protein, multidrug resistance associated proteins, and/or other transporters. Induction and inhibition of these enzymes and transporters are considered as important mechanisms for herb-anticancer drug interactions. Further studies are warranted to investigate potentially harmful herbal interactions with anticancer drugs in patients.
Export Options
About this article
Cite this article as:
Yang An-Kui, He Shu-Ming, Liu Liang, Liu Jun-Ping, Qian Wei Ming and Zhou Shu-Feng, Herbal Interactions with Anticancer Drugs: Mechanistic and Clinical Considerations, Current Medicinal Chemistry 2010; 17 (16) . https://dx.doi.org/10.2174/092986710791111279
DOI https://dx.doi.org/10.2174/092986710791111279 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Platinum Resistant Disease in Ovarian Cancer
Current Medicinal Chemistry Psychopathological Behaviour and Cognition in Morbid Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Exosome-Encapsulated microRNAs as Potential Circulating Biomarkers in Colon Cancer
Current Pharmaceutical Design Intracellular Delivery of Potential Therapeutic Genes: Prospects in Cancer Gene Therapy
Current Gene Therapy Oncolytic HSV-1 Virotherapy: Clinical Experience and Opportunities for Progress
Current Pharmaceutical Biotechnology Recent Advances in Protein and Peptide Drug Delivery: A Special Emphasis on Polymeric Nanoparticles
Protein & Peptide Letters Modulation of DNA Damage Checkpoint; Patenting and Possible Application for Cancer Medicine
Recent Patents on DNA & Gene Sequences Anomalous Products in the Halogenation Reactions of Vinca Alkaloids
Current Organic Chemistry Unusual Food Allergy: AlioideaAllergic Reactions Overview
Recent Patents on Inflammation & Allergy Drug Discovery Nanoparticles-Based Treatment for Bone Metastasis
Current Drug Targets Advances in Anti-inflammatory Activity, Mechanism and Therapeutic Application of Ursolic Acid
Mini-Reviews in Medicinal Chemistry Detecting Growing Mammary Tumors with Monoclonal Antibodies Against Vascular Endothelial Growth Factor Receptor – 3
Current Radiopharmaceuticals Human Leukocyte Antigen (HLA) Pharmacogenomic Tests: Potential and Pitfalls
Current Drug Metabolism Anthrax Fusion Protein Therapy of Cancer
Current Protein & Peptide Science Metabolic Targets of Cardiac HormonesTherapeutic Anti-Cancer Effects
Current Pharmaceutical Design Recent Advances in Oncological Submissions of Dendrimer
Current Pharmaceutical Design Radiosynthesis of N.C.A. Sodium [18F]Fluoroacetate and Radiopharmacological Characterization in Rats and Tumor-Xenografted Mice
Current Radiopharmaceuticals Discovery of New Biomarkers of Cancer Using Proteomics Technology
Current Cancer Therapy Reviews Nutrient and Qualitative Phytochemical Analysis-evaluation of Antimicrobial Activity and Development of Products with Mulberry Leaves (<i>Mulberry indica</i> L.)
Current Nutrition & Food Science Interactions Between Probiotic Dairy Propionibacteria and the Intestinal Epithelium
Current Immunology Reviews (Discontinued)